Patient population
Women with abnormal cervical cancer screening results were asked to
participate in this study. The inclusion criteria included: 1) women
over 21 years of age; 2) infected
with high-risk strains of HPV
(including type 16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, 66, 68) and/or with abnormal cytological
examination (atypical squamous cells of undetermined significance, ASCUS
or worse); 3) were willing and able to sign the informed consent. The
exclusion criteria included:1) women were breast-feeding or pregnant; 2)
allergy to TMTP1-PEG-ICG, acetic acid,
Lugol’s
iodine or alcohol; 3) diagnosis of vaginitis or other sexually
transmitted diseases makes it unsuitable for biopsy sampling; 4) with
severe heart failure, liver insufficiency or renal insufficiency; 5)
participated in another clinical trial with an investigational drug
within 3 months. In addition, patients with the vaginal lesions were not
included in the final statistical analysis.